text: Immediately after his Ph.D, in 1980, René Roy joined the National Research Council (NRC) in Ottawa where he worked as researcher in the Institute for Biological Sciences. Then, in 1985, he began his career as professor in the department of chemistry of the University of Ottawa where he served until December 2002. In parallel, he held the positions of Associate Director of the Ottawa-Carleton Chemistry Institute from 1993 to 1996, Director from 1996 to 1999, and again Associate Director in 2000. From 2002 to 2004, he was chairman of the American Chemical Society (ACS) Division of Carbohydrate Chemistry and, in 2005, head of the ACS awards committee.
  In 2008, he returned to Montreal to teach organic chemistry at the Université du Québec à Montréal. There, he also founded the PharmaQAM biopharmaceutical research center which gathers some 50 professors and 17 institutions with common interests in the molecular aspects of medicinal chemistry and drug discovery working on new bioactive molecules, their mechanism of action and the way they are vectorized in vivo. He served as director of PharmaQAM until December 2017.
  During his career, René Roy has co-developed meningitis vaccines, for humans and animals, that led to commercial success. One of them, targeting the Haemophilus influenzae b (HIB) bacteria, has been designed jointly with the Cuban researcher Vincente Verez Bencomo to prevent lethal meningitis and pneumonia in developing countries. It is the first human semi-synthetic glycoconjugate vaccine approved and remains the only one. In use since 2004, more than 34 million doses have been distributed to children in several countries including Vietnam, Syria, Brazil, Venezuela and Angola, eradicating the infectious disease in Cuba.
  Rene Roy is a cofounder of Glycovax Pharma, a biotech company operating in Montreal, developing glycochemistry-based treatments against cancer and other disease with unmet medical needs.